We protect your health through science
Investigation
Immune Presentation and Regulation
Publications
Phenotypic and molecular characterization of IMP-producing Enterobacterales in Spain: Predominance of IMP-8 in Klebsiella pneumoniae and IMP-22 in Enterobacter roggenkampii.
5. Phenotypic and molecular characterization of IMP-producing Enterobacterales in Spain: Predominance of IMP-8 in Klebsiella pneumoniae and IMP-22 in Enterobacter roggenkampii. Autores: Cañada-García JE, Grippo N, de Arellano ER, Bautista V, Lara N, Navarro AM, Cabezas T, Martínez-Ramírez NM, García-Cobos S, Calvo J, Cercenado E, Aracil B, Pérez-Vázquez M, Oteo-Iglesias J; Spanish IMP Study Group. Revista: Front Microbiol. 2022 Sep 28;13:1000787.
DOICARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3.
6. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Autores: Cañada-García JE, Moure Z, Sola-Campoy PJ, Delgado-Valverde M, Cano ME, Gijón D, González M, Gracia-Ahufinger I, Larrosa N, Mulet X, Pitart C, Rivera A, Bou G, Calvo J, Cantón R, González-López JJ, Martínez-Martínez L, Navarro F, Oliver A, Palacios-Baena ZR, Pascual Á, Ruiz-Carrascoso G, Vila J, Aracil B, Pérez-Vázquez M, Oteo-Iglesias J; GEMARA/GEIRAS-SEIMC/REIPI CARB-ES-19 Study Group. Revista: Front Microbiol. 2022 Jun 30;13:918362.
DOICarbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types.
3. Carbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types. Autores: Cañada-García JE, Ramírez de Arellano E, Jiménez-Orellana M, Viedma E, Sánchez A, Alhambra A, Villa J, Delgado-Iribarren A, Bautista V, Lara N, García-Cobos S, Aracil B, Cercenado E, Pérez-Vázquez M, Oteo-Iglesias J. Revista: Antibiotics (Basel). 2023 Jan 6;12(1):107.
DOIInterregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes.
7. Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes. Autores: Moure Z, Lara N, Marín M, Sola-Campoy PJ, Bautista V, Gómez-Bertomeu F, Gómez-Dominguez C, Pérez-Vázquez M, Aracil B, Campos J, Cercenado E, Oteo-Iglesias J; Spanish Linezolid-Resistant Enterococci Collaborating Group. Revista: Int J Antimicrob Agents. 2020 Jun;55(6):105977.
PUBMED DOICarbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
8. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. Autores: Pérez-Vázquez M, Sola-Campoy PJ, Zurita ÁM, Ávila A, Gómez-Bertomeu F, Solís S, López-Urrutia L, Gónzalez-Barberá EM, Cercenado E, Bautista V, Lara N, Aracil B, Oliver A, Campos J, Oteo-Iglesias J; Spanish Antibiotic Resistance Surveillance Program collaborating Group. Revista: Int J Antimicrob Agents. 2020 Jul;56(1):106026.
PUBMED DOIMultidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project).
9. Multidrug-resistant gram-negative bacteria in Spanish ICU patients: clinical and microbiological characterization (MURAN-UCI Project). Autores: Ramirez de Arellano E, López-Causapé C, Delgado-Valverde M, Arroyo Muñoz FJ, Alemparte-Pardavila E, Arca-Suárez J, Ayestarán I, Calvo Montes J, Cañada-Garcia J, Garcia-Cobos S, García-Fernández S, Gijón Cordero D, González-López JJ, Mir-Cros A, Nuvials X, Pérez-Vázquez M, Pomares-de la Peña A, Pampín-Garcia M, Riazzo C, Rodríguez-Gómez J, Rojo-Molinero E, Ruiz-Garbajosa P, Soriano C, Suberviola Cañas B, Taltavull B, Garnacho-Montero J, Oliver Palomo A, Oteo-Iglesias J; MURAN-UCI Spanish group. Revista: Microbiol Spectr. 2026 Feb 3;14(2):e0298725.
PUBMED DOIGenomic analysis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causing infections in children-a Spanish multicenter study.
10. Genomic analysis of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) causing infections in children-a Spanish multicenter study. Autores: García-Cobos S, Seco Alberca N, Bravo-Queipo-de-Llano B, Casquero-García V, Ramírez de Arellano E, Calvo C, Ruíz-Carrascoso G, Falces-Romero I, Larrosa Escartín N, Viñado-Perez B, Martínez-López MÁ, Melendo Pérez S, Ruíz de Gopegui E, Pérez Vázquez S, Carrasco-Colom J, Aracil García B, Pérez-Vázquez M, Méndez-Echevarría A, Oteo Iglesias Revista: J. Front Microbiol. 2025 May 9;16:1534840.
PUBMED DOICarbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types.
13. Carbapenemase-Producing Klebsiella pneumoniae in COVID-19 Intensive Care Patients: Identification of IncL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types. Autores: Cañada-García JE, Ramírez de Arellano E, Jiménez-Orellana M, Viedma E, Sánchez A, Alhambra A, Villa J, Delgado-Iribarren A, Bautista V, Lara N, García-Cobos S, Aracil B, Cercenado E, Pérez-Vázquez M, Oteo-Iglesias J. Revista: Antibiotics (Basel). 2023 Jan 6;12(1):107.
PUBMED DOI
Additional Information
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.